Oruka Therapeutics, Inc. (ORKA) Research

Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.

Market snapshot

Symbol
ORKA
Price
$72.34
Day change
+2.06%
Market cap
$2.7B
P/E ratio
-34.33x
52-week range
10.77-91
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$149.5

Recent news

  • Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance

    Oruka Therapeutics Inc. (NASDAQ:ORKA) shares are up during Monday's premarket session following positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001 for moderate-to-severe plaque psoriasis.

Peer companies

  • AnaptysBio, Inc. (ANAB)
  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • Kodiak Sciences Inc. (KOD)
  • Mind Medicine (MindMed) Inc. (MNMD)
  • Nurix Therapeutics, Inc. (NRIX)
  • Oculis Holding AG (OCS)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • Rapport Therapeutics, Inc. Common Stock (RAPP)

Recent insider activity

  • Agarwal Arjun — M-Exempt (8000 shares) on 2026-06-12
  • Agarwal Arjun — M-Exempt (1459 shares) on 2026-06-12
  • Agarwal Arjun — M-Exempt (1459 shares) on 2026-06-12
  • Agarwal Arjun — M-Exempt (8000 shares) on 2026-06-12
  • Agarwal Arjun — S-Sale (1859 shares) on 2026-06-12

Open Oruka Therapeutics, Inc. (ORKA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.